
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 11.000 | 11.000 | 0.000 |
Stocks | 94.080 | 94.080 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 41.445 | 22.110 |
Price to Book | 3.196 | 2.610 |
Price to Sales | 5.120 | 3.162 |
Price to Cash Flow | 25.014 | 14.735 |
Dividend Yield | 0.156 | 2.148 |
5 Years Earnings Growth | 4.010 | 9.292 |
Name | Net % | Category Average |
---|---|---|
Healthcare | 99.970 | 97.443 |
Basic Materials | 0.010 | 0.609 |
Industrials | 0.010 | 0.614 |
Technology | 0.010 | 0.318 |
Number of long holdings: 91
Number of short holdings: 1
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Beigene | CNE100005XT6 | 9.58 | 250.78 | +1.04% | |
Jiangsu Hengrui | CNE0000014W7 | 9.10 | 51.04 | +0.37% | |
InnoCare Pharma | CNE100005P56 | 9.04 | 18.48 | -2.69% | |
Dizal Jiangsu Pharmaceutical | CNE1000055W8 | 7.04 | 52.03 | -1.87% | |
Shouyao Holdings Beijing | CNE1000062V6 | 6.32 | 32.71 | -0.88% | |
Sichuan Biokin Pharmaceutical | CNE100006FN4 | 5.84 | 250.25 | +1.32% | |
Gan Lee Pharmaceuticals | CNE100003ZH1 | 5.61 | 46.11 | -0.62% | |
RemeGen | CNE100005B03 | 5.51 | 43.78 | -1.40% | |
Suzhou Zelgen Biopharma | CNE100003RP1 | 5.00 | 109.00 | +0.55% | |
Hinova Pharmaceuticals | CNE1000059F5 | 4.52 | 42.20 | +3.33% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Penghua Jiangxin Sele Alloc C | 7.49B | -0.77 | -7.46 | - | ||
Penghua HongKang mix A | 4.11B | -0.08 | 2.73 | - | ||
Penghua HongKang mix C | 4.11B | -0.10 | 2.63 | - | ||
Penghua HK Bank Index LOF | 4.08B | 8.85 | 12.92 | - | ||
Penghua CSI Guofang Idx Classified | 3.2B | -3.23 | -12.70 | -3.10 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review